|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marshall AL and Christiani DC: Genetic
susceptibility to lung cancer-light at the end of the tunnel?
Carcinogenesis. 34:487–502. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wistuba II, Gelovani JG, Jacoby JJ, Davis
SE and Herbst RS: Methodological and practical challenges for
personalized cancer therapies. Nat Rev Clin Oncol. 8:135–141. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tiong KH, Mah LY and Leong CO: Functional
roles of fibroblast growth factor receptors (FGFRs) signaling in
human cancers. Apoptosis. 18:1447–1468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Monaco SE, Rodriguez EF, Mahaffey AL and
Dacic S: FGFR1 amplification in squamous cell carcinoma of the lung
with correlation of primary and metastatic tumor status. Am J Clin
Pathol. 145:55–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Young RJ, Lim AM, Angel C, Collins M, Deb
S, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, et al:
Frequency of fibroblast growth factor receptor 1 gene amplification
in oral tongue squamous cell carcinomas and associations with
clinical features and patient outcome. Oral Oncol. 49:576–581.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ishizuka T, Tanabe C, Sakamoto H, Aoyagi
K, Maekawa M, Matsukura N, Tokunaga A, Tajiri T, Yoshida T, Terada
M and Sasaki H: Gene amplification profiling of esophageal squamous
cell carcinomas by DNA array CGH. Biochem Biophys Res Commun.
296:152–155. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gru AA and Allred DC: FGFR1 amplification
and the progression of non-invasive to invasive breast cancer.
Breast Cancer Res. 14:1162012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM,
Lee CY, Rha SY, Bae MK, Lee YJ, Kim SH, et al: Fibroblast growth
factor receptor 1 gene amplification is associated with poor
survival and cigarette smoking dosage in patients with resected
squamous cell lung cancer. J Clin Oncol. 31:731–737. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Cai Y, Ji J, Liu Z, Zhao C, Zhao
Y, Wei T, Shen X, Zhang X, Li X and Liang G: Discovery and
identification of new non-ATP competitive FGFR1 inhibitors with
therapeutic potential on non-small-cell lung cancer. Cancer Lett.
344:82–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pu D, Liu J, Li Z, Zhu J and Hou M:
Fibroblast growth factor receptor 1 (FGFR1), partly related to
vascular endothelial growth factor receptor 2 (VEGFR2) and
microvessel density, is an independent prognostic factor for
non-small cell lung cancer. Med Sci Monit. 23:247–257. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kawahara Y: Human diseases caused by
germline and somatic abnormalities in microRNA and microRNA-related
genes. Congenit Anom (Kyoto). 54:12–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kasinski AL and Slack FJ: miRNA-34
prevents cancer initiation and progression in a therapeutically
resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
Cancer Res. 72:5576–5587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fortunato O, Boeri M, Moro M, Verri C,
Mensah M, Conte D, Caleca L, Roz L, Pastorino U and Sozzi G:
Mir-660 is downregulated in lung cancer patients and its
replacement inhibits lung tumorigenesis by targeting MDM2-p53
interaction. Cell Death Dis. 5:e15642014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peng Y, Dai Y, Hitchcock C, Yang X, Kassis
ES, Liu L, Luo Z, Sun HL, Cui R, Wei H, et al: Insulin growth
factor signaling is regulated by microRNA-486, an underexpressed
microRNA in lung cancer. Proc Natl Acad Sci USA. 110:15043–15048.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang J, Li J, Wang X, Zheng C and Ma W:
Downregulation of microRNA-214 and overexpression of FGFR-1
contribute to hepatocellular carcinoma metastasis. Biochem Biophys
Res Commun. 439:47–53. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang H, Qu L, Wang Y, Cong J, Wang W and
Yang X: miR-99a promotes proliferation targeting FGFR3 in human
epithelial ovarian cancer cells. Biomed Pharmacother. 68:163–169.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishijima N, Seike M, Soeno C, Chiba M,
Miyanaga A, Noro R, Sugano T, Matsumoto M, Kubota K and Gemma A:
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small
cell lung cancer cells. Int J Oncol. 48:937–944. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen QY, Jiao DM, Yan L, Wu YQ, Hu HZ,
Song J, Yan J, Wu LJ, Xu LQ and Shi JG: Comprehensive gene and
microRNA expression profiling reveals miR-206 inhibits MET in lung
cancer metastasis. Mol Biosyst. 11:2290–2302. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang R, Chen XF and Shu YQ: Prediction of
non-small cell lung cancer metastasis-associated microRNAs using
bioinformatics. Am J Cancer Res. 5:32–51. 2014.PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu F, Liu H, Xie X, Mei J and Wang M:
Activated cdc42-associated kinase is up-regulated in non-small-cell
lung cancer and necessary for FGFR-mediated AKT activation. Mol
Carcinog. 55:853–863. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jung SY, Yi JY, Kim MH, Song KH, Kang SM,
Ahn J, Hwang SG, Nam KY and Song JY: IM-412 inhibits the invasion
of human breast carcinoma cells by blocking FGFR-mediated
signaling. Oncol Rep. 34:2731–2737. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao D, Lu Y, Yang C, Zhou X and Xu Z:
Activation of FGF receptor signaling promotes invasion of
non-small-cell lung cancer. Tumour Biol. 36:3637–3642. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Theelen WS, Mittempergher L, Willems SM,
Bosma AJ, Peters DD, van der Noort V, Japenga EJ, Peeters T, Koole
K, Šuštić T, et al: FGFR1, 2 and 3 protein overexpression and
molecular aberrations of FGFR3 in early stage non-small cell lung
cancer. J Pathol Clin Res. 2:223–233. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Göke A, Franzen A, Menon R, Goltz D,
Kirsten R, Boehm D, Vogel W, Scheble V, Ellinger J, Gerigk U, et
al: Rationale for treatment of metastatic squamous cell carcinoma
of the lung using fibroblast growth factor receptor inhibitors.
Chest. 142:1020–1026. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tran TN, Selinger CI, Kohonen-Corish MR,
McCaughan BC, Kennedy CW, O'Toole SA and Cooper WA: Fibroblast
growth factor receptor 1 (FGFR1) copy number is an independent
prognostic factor in non-small cell lung cancer. Lung Cancer.
81:462–467. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dutt A, Ramos AH, Hammerman PS, Mermel C,
Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, et
al: Inhibitor-sensitive FGFR1 amplification in human non-small cell
lung cancer. PLoS One. 6:e203512011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wynes MW, Hinz TK, Gao D, Martini M, Marek
LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, et al:
FGFR1 mRNA and protein expression, not gene copy number, predict
FGFR TKI sensitivity across all lung cancer histologies. Clin
Cancer Res. 20:3299–3309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang J, Zhao H, Xin Y and Fan L:
MicroRNA-198 inhibits proliferation and induces apoptosis of lung
cancer cells via targeting FGFR1. J Cell Biochem. 115:987–995.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang C, Ma R, Yue J, Li N, Li Z and Qi D:
MiR-497 suppresses YAP1 and inhibits tumor growth in non-small cell
lung cancer. Cell Physiol Biochem. 37:342–352. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA,
Wang B, Lu MY, Pan CK and Chen P: Downregulation of miR-497
promotes tumor growth and angiogenesis by targeting HDGF in
non-small cell lung cancer. Biochem Biophys Res Commun.
435:466–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gu A, Lu J, Wang W, Shi C, Han B and Yao
M: Role of miR-497 in VEGF-A-mediated cancer cell growth and
invasion in non-small cell lung cancer. Int J Biochem Cell Biol.
70:118–125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Han Z, Zhang Y, Yang Q, Liu B, Wu J, Zhang
Y, Yang C and Jiang Y: miR-497 and miR-34a retard lung cancer
growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget.
6:13149–13163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yin Q, Han Y, Zhu D, Li Z, Shan S, Jin W,
Lu Q and Ren T: miR-145 and miR-497 suppress TGF-β-induced
epithelial-mesenchymal transition of non-small cell lung cancer by
targeting MTDH. Cancer Cell Int. 18:1052018. View Article : Google Scholar : PubMed/NCBI
|
